Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

NCT00428389 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

262

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Rivastigmine 5 cm^2 transdermal patch
DRUG: Rivastigmine 10 cm^2 transdermal patch

Sponsor

Novartis